Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023211058> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2023211058 abstract "As with other drugs, applications for marketing approval of new chemopreventive agents in the United States must include data from adequate and well-controlled clinical trials that demonstrate effectiveness and safety for the intended use. Knowledge of a drug's pharmacologic actions and metabolism may benefit protocol design, by identifying the patient populations and dosing schedules associated with a favorable risk/benefit profile. With availability of appropriate preclinical data, including standard assessments of an agent's toxicology, effects on reproductive performance, and genotoxicity, initial Phase I studies of 1-3 months may be performed in normal volunteers or an appropriate higher risk population. For chronic dosing studies of longer duration, preclinical toxicology studies of longer duration are relevant. Enrollment in chemoprevention studies should be directed toward individuals at sufficient risk of developing cancer so that potential benefit may counterbalance the unpredictable and possibly serious adverse effects that may be observed with prolonged administration of a study drug. Phase I and II studies with clinical dosing lasting up to 12 months often afford opportunities to assess drug effect on surrogate endpoint biomarkers that may correlate with endpoints of clinical effectiveness. Phase III and late phase II chemopreventive investigations should routinely utilize a prospective, randomized study design (double-masked and placebo-controlled, when possible). To support marketing approval, there must be evidence that a chemopreventive agent significantly delays or prevents the occurrence of malignancy, with acceptable safety. In some circumstances, modulation of a surrogate marker may provide a basis for marketing approval, before more definitive endpoint data become available. However, the acceptability of a surrogate depends on the nature and quality of the data supporting its predictive value. Given the considerations of large study size, long duration, and high cost that may hamper development of potential agents, studies designed to examine the predictive value of surrogate endpoint biomarkers are of great importance to the future development of chemoprevention research." @default.
- W2023211058 created "2016-06-24" @default.
- W2023211058 creator A5020605834 @default.
- W2023211058 creator A5028801403 @default.
- W2023211058 creator A5031196656 @default.
- W2023211058 creator A5040994580 @default.
- W2023211058 creator A5079473609 @default.
- W2023211058 creator A5079542734 @default.
- W2023211058 date "1997-01-01" @default.
- W2023211058 modified "2023-10-16" @default.
- W2023211058 title "Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents" @default.
- W2023211058 cites W1525444530 @default.
- W2023211058 cites W1994059421 @default.
- W2023211058 cites W1996656481 @default.
- W2023211058 cites W2044282408 @default.
- W2023211058 cites W2044646650 @default.
- W2023211058 cites W2072179690 @default.
- W2023211058 cites W2079495711 @default.
- W2023211058 cites W2153399329 @default.
- W2023211058 cites W2161427454 @default.
- W2023211058 cites W3016408864 @default.
- W2023211058 cites W37657173 @default.
- W2023211058 doi "https://doi.org/10.1002/(sici)1097-4644(1997)27+<1::aid-jcb3>3.0.co;2-2" @default.
- W2023211058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9591186" @default.
- W2023211058 hasPublicationYear "1997" @default.
- W2023211058 type Work @default.
- W2023211058 sameAs 2023211058 @default.
- W2023211058 citedByCount "1" @default.
- W2023211058 crossrefType "journal-article" @default.
- W2023211058 hasAuthorship W2023211058A5020605834 @default.
- W2023211058 hasAuthorship W2023211058A5028801403 @default.
- W2023211058 hasAuthorship W2023211058A5031196656 @default.
- W2023211058 hasAuthorship W2023211058A5040994580 @default.
- W2023211058 hasAuthorship W2023211058A5079473609 @default.
- W2023211058 hasAuthorship W2023211058A5079542734 @default.
- W2023211058 hasConcept C126322002 @default.
- W2023211058 hasConcept C141341695 @default.
- W2023211058 hasConcept C142724271 @default.
- W2023211058 hasConcept C143998085 @default.
- W2023211058 hasConcept C148482608 @default.
- W2023211058 hasConcept C177713679 @default.
- W2023211058 hasConcept C197934379 @default.
- W2023211058 hasConcept C203092338 @default.
- W2023211058 hasConcept C204787440 @default.
- W2023211058 hasConcept C27081682 @default.
- W2023211058 hasConcept C2777288759 @default.
- W2023211058 hasConcept C2780035454 @default.
- W2023211058 hasConcept C2780385302 @default.
- W2023211058 hasConcept C2908647359 @default.
- W2023211058 hasConcept C535046627 @default.
- W2023211058 hasConcept C71924100 @default.
- W2023211058 hasConcept C98274493 @default.
- W2023211058 hasConcept C99454951 @default.
- W2023211058 hasConceptScore W2023211058C126322002 @default.
- W2023211058 hasConceptScore W2023211058C141341695 @default.
- W2023211058 hasConceptScore W2023211058C142724271 @default.
- W2023211058 hasConceptScore W2023211058C143998085 @default.
- W2023211058 hasConceptScore W2023211058C148482608 @default.
- W2023211058 hasConceptScore W2023211058C177713679 @default.
- W2023211058 hasConceptScore W2023211058C197934379 @default.
- W2023211058 hasConceptScore W2023211058C203092338 @default.
- W2023211058 hasConceptScore W2023211058C204787440 @default.
- W2023211058 hasConceptScore W2023211058C27081682 @default.
- W2023211058 hasConceptScore W2023211058C2777288759 @default.
- W2023211058 hasConceptScore W2023211058C2780035454 @default.
- W2023211058 hasConceptScore W2023211058C2780385302 @default.
- W2023211058 hasConceptScore W2023211058C2908647359 @default.
- W2023211058 hasConceptScore W2023211058C535046627 @default.
- W2023211058 hasConceptScore W2023211058C71924100 @default.
- W2023211058 hasConceptScore W2023211058C98274493 @default.
- W2023211058 hasConceptScore W2023211058C99454951 @default.
- W2023211058 hasLocation W20232110581 @default.
- W2023211058 hasLocation W20232110582 @default.
- W2023211058 hasOpenAccess W2023211058 @default.
- W2023211058 hasPrimaryLocation W20232110581 @default.
- W2023211058 hasRelatedWork W1991934106 @default.
- W2023211058 hasRelatedWork W2023211058 @default.
- W2023211058 hasRelatedWork W2055940634 @default.
- W2023211058 hasRelatedWork W2158158187 @default.
- W2023211058 hasRelatedWork W2270032817 @default.
- W2023211058 hasRelatedWork W2624952492 @default.
- W2023211058 hasRelatedWork W2767085437 @default.
- W2023211058 hasRelatedWork W2795021885 @default.
- W2023211058 hasRelatedWork W4206732464 @default.
- W2023211058 hasRelatedWork W4225374871 @default.
- W2023211058 isParatext "false" @default.
- W2023211058 isRetracted "false" @default.
- W2023211058 magId "2023211058" @default.
- W2023211058 workType "article" @default.